KPC Pharmaceuticals' (SHA:600422) attributable profit rose 20% to 648.1 million yuan in 2024 from 540.7 million yuan in 2023.
Earnings per share at the drug company increased 21% to 0.86 yuan from 0.71 yuan in the previous year, according to a Tuesday filing by parent China Resources Pharmaceutical (HKG:3320) with the Hong Kong bourse.
Revenue slipped 0.3% to 8.40 billion yuan from 8.43 billion yuan a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。